The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF). KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered… Read More
An investigational one-time gene therapy for the treatment of adults with severe haemophilia A has been proven to be effective for more than three years from treatment. BioMarin Pharmaceutical revealed the positive results from its ongoing global Phase III GENEr8-1 study of Roctavian (valoctocogene roxaparvovec). … Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma. Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More
Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe. The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More
Terebellum and NeurosolvTherapeutics will partner to launch Perineline, a new patented two-part therapy for spinal cord injuries. The drug has attained EMA Orphan Designation and it is hoped that it will revolutionise the therapeutic treatment and resulting end patient outcomes from spinal cord injuries. Terebellum will contribute strategic guidance in… Read More
The European Commission (EC) has granted marketing authorisation for Alnylam Pharmaceuticals’ AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The RNAi therapeutic has been approved in adult patients with stage 1 or stage 2 polyneuropathy, following positive 18-month results from the HELIOS-A Phase III study. AMVUTTRA significantly improved… Read More
Nefecon has become the first and only approved treatment in the EU for primary immunoglobulin A nephropathy (IgAN), a rare, progressive kidney disease. The European Medicines Agency said that the medicine “was shown to be effective at lowering the level of excess protein in the urine in patients with IgAN,… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology so that it is activated predominantly in… Read More
The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More
Image: Fabio Centogene and Molecular Health, are to collaborate on the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project, starting with epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based… Read More
ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an… Read More
Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More
Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More
The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries… Read More
Integrated Platform Drug Discovery and Development Companies - Part 1 By Dr Urban A. Kiernan and Dr Stephen Naylor Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms… Read More